Multicentre Phase I Trial of Engineered T Cells for Patients With Relapsed or Refractory Primary Cutaneous CD30+ Large T Cell Lymphoma or Transformed CD30+ Mycosis Fungoides — TECLA  

CD30 Positive Cutaneous T Cell Lymphoma Clinical Trial

Official title: Multicentre Phase I Trial of Engineered T Cells for Patients With Relapsed or Refractory Primary Cutaneous CD30+ Large T Cell Lymphoma or Transformed CD30+ Mycosis Fungoides

Status Not yet recruiting

Clinical Trial Summary

Patients with cutaneous CD30 positive lymphoma will receive systemical and topical treatment with their own genetically modified T cells. Treatment evaluation consists of assessment of safety and preliminary evidence of response.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• CD30 Positive Cutaneous T Cell Lymphoma
• CD30 Positive Transformed Mycosis Fungoides
• Lymphoma
• Lymphoma, Primary Cutaneous Anaplastic Large Cell
• Lymphoma, T-Cell
• Lymphoma, T-Cell, Cutaneous
• Mycoses
• Mycosis Fungoides

• NCT number: NCT01645293
• Study type: Interventional
• Source: University of Cologne
• Contact: Michael Hoffmann, MD
• Email: michael.hoffmann@uk-koeln.de
• Status: Not yet recruiting
• Phase: Phase 1